The loss of NPC1 protein function is the predominant cause of Niemann-Pick type C1 disease 
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The concerted activities of NPC1 and NPC2 proteins are essential to intracellular mobilization of unesterified cholesterol and other lipids 4, 5 . Loss of either NPC1 or NPC2 function results in distinctive intracellular accumulation of cholesterol and glycosphingolipids in late endosomes and lysosomes. The onset of the disease can occur at any age, but it typically manifests in childhood with an early death by adolescence. Degeneration of cerebellar Purkinje neurons is a prominent early feature in the disease progression, which leads to clinical symptoms of motor impairments that include cerebellar ataxia, dysarthria and dysphagia 3 . Dementia is a late stage feature of NP-C due to the loss of hippocampal and cortical neurons [6] [7] [8] .
Transition metals such as iron, manganese, copper, and zinc are integral to diverse biological processes including neurotransmission, myelination, synaptogenesis, DNA transcription, respiration, and antioxidant defense. Dysregulation of essential redox-active metals such as copper and iron, can enhance toxic Fenton and Haber-Weiss reactions, and generate reactive oxygen species (ROS) 9 . Oxidative stress is a pathological feature of NP-C [10] [11] [12] [13] [14] .
Notably, there is an elevation of non-enzymatically produced oxysterols in NP-C 15 , which could be a product of perturbed metal homeostasis.
Emerging data indicate an imbalance of metal ions in NP-C1. Skin fibroblast cells derived from NP-C1 patients have up-regulated gene expression of metalloproteins involved in copper (copper-transporting ATPase 1 (ATP7A)), iron (ferritin and sideroflexin 1) and zinc (zinc
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transporter ZIP2) metabolism 11 . Recent studies reported elevated copper levels in the liver and plasma of the Npc1 -/-mouse model, concomitant with an increase in plasma ceruloplasmin (CP) levels 12, 16 . However, these findings are inconsistent with a case report of an NP-C1 patient who had elevated serum free copper with low CP 17 . An alternative explanation is that the low serum CP in this patient results from defective NPC1-dependent trafficking of the copper transporter ATP7B in hepatic cells from the late endosomes to the secretory pathway 18, 19 , where ATP7B
facilitates copper incorporation into CP. CP plays an important role in iron export 20 . There is a lack of ferritin immunoreactivity in spleen, liver, and fetal tissues from human NP-C cases,
suggesting that tissue iron is not properly regulated in NP-C [21] [22] [23] 
Human tissue and biological fluid samples
Post-mortem human brain tissues (cerebellum and hippocampus) from NP-C cases and matched non-NP-C control subjects (n (hippocampus) = 5/diagnostic group; n (cerebellum) = 4/diagnostic group); 
Page 5 of 38 Metallomics

Metal analysis
Metal content in CSF, plasma and tissues samples were analyzed using inductivelycoupled plasma mass spectrometry (ICP-MS) as previously described 25 . Lyophilized human and murine tissue (~40 -600 mg wet weight or ~5 -40 mg dry weight), CSF (100 µL) and plasma (50 µL) samples were pre-digested overnight in 50 µL of concentrated HNO 3 (Aristar Grade, BDH), followed by heating to 90°C for 20 min. The acid digested tissue, CSF and plasma samples were diluted with 1% HNO 3 , and metal content was measured using a 7700x
ICP-MS (Agilent). The instrument was calibrated using certified ICP-MS standard solutions (AccuStandard) containing 0, 10, 50, 100, and 500 ppb of all elements measured in 1% HNO 3 .
Metal content in limited CSF samples were confirmed by inductively-coupled plasma optical emission spectrometry (ICP-OES) 26 (data not shown). For ICP-OES analysis, the CSF sample (1 mL) was digested overnight in OmniTrace 70% HNO 3 (EMD) with heating at 60°C and shaking at 200 rpm, then diluted to 5% HNO 3 with OmniTrace water. Then the samples were analyzed for elemental analysis (similar to ICP-MS) using a Vista Pro ICP-OES (Varian, Inc).
Elemental values were calibrated using National Institute of Standards and Technology (NIST)-traceable elemental standards and validated using NIST-traceable 1577b bovine liver reference material. Cesium (50 ppm) was used for ionization suppression and yttrium (5 ppm) was used as an internal standard. Data was collected and summarized using native software (ICP Expert;
Varian, Inc).
Quantification of ceruloplasmin
Western blotting was used to identify total, apo-and holo-CP in both CSF and plasma samples as previously described 27 . Heparinized plasma samples were diluted 100-fold with 
Plasma ceruloplasmin oxidase activity
Plasma ceruloplasmin oxidase activity was assayed using a modified protocol for 96-well plates based on that previously described 28 . Briefly, 5 µL of each plasma sample was pre- The absorbance at 540 nm of the oxidized product was measured using a PowerWave microplate spectrometer (BioTek). CP oxidase activity was calculated as the difference between the total and azide-resistant oxidase activities.
Statistical analysis
Human clinical data analyses were performed with R version 2.15.2 29 , using the following packages, multcomp 30 , effects 30 and ggplot2 31 . The data were checked for normality.
Those that showed a deviation were transformed as required by BoxCox transformation 32 . For categorical variables such as gender, a chi-square test was performed to assess the distribution across the defined groups. Analysis of variance was used to assess any age difference between the groups. For all other continuous variables, analysis of co-variance (ANCOVA) was Figure 1 and Table S1 ).
RESULTS
Extensive metal dyshomeostasis in tissues of
Iron levels were significantly decreased in Npc1 -/-liver (29 ± 5%; p < 0.0001) and spleen (18 ± 4%; p < 0.0001) compared to WT. These results were consistent with previous studies that reported a lack of ferritin in these tissues from human NP-C cases [21] [22] [23] , indicating a functional iron deficiency. In contrast, we found a moderate iron accumulation in the cerebellum (16 ± 3%; p < 0.0001) and cerebrum (22 ± 2%; p < 0.0001) of Npc1 -/-mice. There was no difference in iron levels in the lung, heart and kidney.
Copper levels were significantly altered in each tissue analyzed. Copper was significantly increased in the liver (23 ± 4%; p< 0.0001) and in the lung (170 ± 17%; p < 0.0001)
of Npc1 -/-mice compared to WT. A moderate but significant copper deficiency was observed in all other tissues examined, with reductions in Npc1 -/-cerebellum (16 ± 3%; p < 0.0001), cerebrum (15 ± 2%; p < 0.0001), spleen (10 ± 4%; p = 0.01), kidney (14 ± 2%; p < 0.0001), and have also contributed to the discrepant result.
Zinc levels were increased in the Npc1 -/-mouse cerebellum (14 ± 3%; p < 0.0001) and cerebrum (12 ± 2%; p < 0.0001) relative to WT. The liver (24 ± 2%; p < 0.0001) and the lung (28 ± 6%; p < 0.0001) of Npc1 -/-mice were markedly decreased in zinc, and to a lesser extent in the spleen (7 ± 3%; p = 0.03) and kidney (9 ± 2%; p < 0.0001), compared to WT.
There was a significant accumulation of manganese content in the cerebellum (23 ± 3%; p < 0.0001) and cerebrum (21 ± 3%; p < 0.0001) of Npc1 -/-mice compared to WT. Manganese was also significantly increased to a lesser extent in the spleen (14 ± 7%; p = 0.03) and the heart (7 ± 3%; p = 0.02) of Npc1 -/-mice. In contrast, there was a reduction in the Npc1 -/-mouse liver (14 ± 2%; p < 0.0001) and lung (15 ± 6%; p = 0.02) manganese concentration.
Aberrant metal levels and ceruloplasmin abnormalities in Npc1 -/-mice plasma
We analyzed the metal content of plasma samples collected from pre-and symptomatic female Npc1 -/-and WT littermate control mice at P21 and P49, respectively. There was a trend to an age-dependent rise in plasma iron concentration in both genotypes, but not statistically significant ( Figure 2A and Table S2 ). Our observation of a 34 ± 7% increase (p < 0.0001) in plasma copper at P49 in Npc1 -/-mice compared to WT ( Figure 2B and Table S2 ) was consistent with that previously reported 16 . Furthermore, we identified a marked age-dependent elevation of plasma copper in Npc1 -/-mice that was not observed in WT animals ( Figure 2B and Table S2 ).
In contrast, we found an elevation in plasma zinc in pre-symptomatic Npc1 -/-mice at P21 ( Figure   2C and Table S2 ). At the symptomatic age of P49, plasma zinc in Npc1 -/-mice fell to a level comparable to that of WT.
CP is a key protein linked to both copper and iron metabolism 33 . It requires six copper atoms to form the stable and active holo-CP species 34 , which is central to its ferroxidase activity and cellular iron export by catalyzing the oxidation of ferrous to ferric iron 35 . Therefore, impaired copper homeostasis can negatively affect the synthesis and activity of holo-CP, and subsequently iron homeostasis. We quantified total, apo-and holo-CP levels in the plasma by western blotting ( Figure S1 ). In parallel with the elevated plasma copper levels at P49 in Npc1
-/-mice, we also observed a 49 ± 4% increase (p = 0.0004) in total CP compared to WT ( Figure 2D ).
This was also reflected in a concomitant 53 ± 7% increase (p < 0.0001)in total oxidase activity, the sum of azide-sensitive activity (attributed to CP, and known as ferroxidase I) and azideresistant activity (ferroxidase II, which is proportionally more in mice than in humans) 36 ( Figure   2E ). Although there was no age-dependent change in total CP levels in Npc1 -/-mice, there was an age-dependent increase in the copper-bound active holo-CP level and a decrease in the unmetallated apo-CP level ( Figure 2F ). These changes in apo-and holo-CP levels were reflected in the age-dependent increase in total (azide-sensitive plus -insensitive) and CP oxidase (azidesensitive) activities observed in Npc1 -/-mouse plasma (2E and 2G).
Zinc accumulates in the human NP-C disease patient cerebellum
To assess the potential of dysregulated metal homeostasis to be a contributing factor to neurodegeneration in NP-C patients, we analyzed the metal content of brain tissues, CSF and plasma. The cerebellum and hippocampus have significant neuropathology in NP-C disease [6] [7] [8] .
We obtained post-mortem cerebellar (n = 4/diagnostic group) and hippocampal (n = 5/diagnostic group) tissues from NP-C cases and matched non-NP-C controls (Table S3) . Limited availability of post-mortem NP-C disease brain tissue samples restricted the power of this study.
While the sample sizes are small, and having determined that there were no effects of gender or age, these factors were not included in the analysis of data presented. We found a significant elevation of zinc (28 ± 10%; p = 0.03) in NP-C cerebellar tissue compared to non-NP-C control tissues ( Figure 3 and Table S4 ). There was a possible trend to elevated iron levels in the NP-C cerebellum compared to controls (p = 0.06). In the hippocampus, there was no significant difference in transition metals measured between NP-C and control samples, but a possible trend towards an increase in zinc (p = 0.09).
NP-C1 cerebrospinal fluid is deficient in transition metal
We also evaluated CSF transition metal levels in 21 NP-C1 disease patients. A third of the NP-C1 subjects were treated with miglustat (Table S5) , an inhibitor of glycosphingolipid synthesis and the only drug shown in a controlled clinical trial to have some efficacy for NP-C 37, 38 . Therefore, we also analyzed the effect of miglustat treatment on CSF metal levels. Since control CSF samples from healthy individuals, particularly pediatric samples, are impractically rare, we used published reference range values 39 as a comparison for the NP-C1 CSF metal levels.
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Relative to the reference range, the majority of the NP-C1 CSF samples analyzed were deficient in the essential transition metals iron, copper and zinc ( Figure 4B , 4C, 4D and Table   S5 ). The mean CSF manganese concentration was just below the lower reference limit ( Figure   4A ; Table S5 ). Miglustat treatment had no effect on CSF metal concentrations. There was no association between levels of these metal ions and disease severity or age. The deficiency of transition metals was confirmed using samples that were measured in a separate lab using inductively-coupled plasma optical emission spectrometry (ICP-OES; data not shown). The apparent deficiency of transition metals in the CSF may indicate a failure of essential metal homeostasis in the central nervous system of NP-C1 patients.
CSF ceruloplasmin levels correlate with NP-C1 disease severity
To determine whether the apparent CSF copper and iron deficiencies affect the level of CP in the CSF of NP-C1 patients, we quantified CSF total, apo-and holo-CP levels by western blotting ( Figure S2A ). It was noteworthy that, despite an apparent copper deficiency in the CSF, the estimated CSF total CP concentration in NP-C1 patients was slightly higher than the reference range (Table S5) . We found a significant positive correlation between NP-C1 disease severity and CSF total CP and holo-CP concentrations ( Figure 5A ). An increase in 1 nM of total CP and holo-CP corresponded to an increase of 2 ± 1 and 2.7 ± 0.9 points in clinical severity score 40 , respectively. Thus, CSF total CP and holo-CP may be useful biomarkers of NP-C1 disease progression.
We further examined the association between CSF CP species with CSF metal ions.
Unlike plasma, there was no correlation between copper and total CP or holo-CP in the NP-C1
CSF samples ( Figure 5B ). Interestingly, we found a modest, but significant negative correlation between copper and apo-CP ( Figure 5B ). We also found significant negative correlations between NP-C1 CSF manganese and total CP or holo-CP levels, which was independent of miglustat treatment ( Figure 5C ). These relationships were adjusted for age and gender.
Significantly decreased plasma metal concentrations in NP-C1
Next, we appraised NP-C1 patient plasma metal levels. We found, compared to matched non-NP-C healthy controls (HC), NP-C1 cases had slightly lower plasma manganese, iron and zinc ( Figure 6 and Table S6 ). In particular, values below the reference range for plasma zinc were frequent in NP-C1 patients (12%), and uncommon in the HC (5%; p = 0.04). Miglustat treatment did not impact on any of these changes. Although there was a slight decrease in the plasma copper concentration in the NP-C1 cases, the mean concentration difference was not statistically different to that of HC (Table S6) .
Miglustat treatment affects holo-CP formation and specific oxidase activity CP is a major copper-carrying protein in the blood 41, 42 , and it is sometimes used as an indirect indicator of serum and plasma copper levels. On the basis of the disparate findings of serum/plasma copper changes between our study and a case study that reported an elevation in serum free copper 17 , we further investigated the change in human plasma CP. We found that there was no significant difference in plasma total CP concentration between HC and both NP-C1 groups ( Figure 7A , Figure S2B and Table S6 ). However, further separating CP into the active copper-bound holo-CP and unmetallated apo-CP species, we found that miglustat treatment resulted in a small, but significant, increase in plasma holo-CP concentration in the NP-C1 patients ( Figure 7B and Table S6 ), while there was no difference in the mean apo-CP concentration between the three groups ( Figure 7C and Table S6 ).
Stable and active CP requires binding of six copper atoms 34 . Our calculation of the mean plasma Cu:total CP and Cu:holo-CP ratios for HC approximated the expected ratio of six ( Figure   7D , 7E and Table S6 ). Consistent with the plasma copper data, the plasma Cu:total CP and Cu:holo-CP ratios for NP-C1 patients not treated with miglustat did not deviate significantly from that of the HC ( Figure 7D and 7E) . It is noteworthy that NP-C1 patients treated with miglustat had significantly decreased plasma Cu:total CP and Cu:holo-CP ratios compared to HC and NP-C1 patients not treated with miglustat ( Figure 7D and 7E). The decrease in plasma Cu:holo-CP ratio in NP-C1 patients treated with miglustat was paralleled by a small but significant decrease in holo-CP specific oxidase activity ( Figure 7F ).
Interestingly, we found a negative association between NP-C1 disease severity and plasma apo-CP concentration that was gender-dependent (female only) but miglustatindependent ( Figure 7G ). However, there was a significant difference in severity score that was miglustat-dependent after adjusting for gender and apo-CP concentration (p < 0.0002). Overall, NP-C1 patients treated with miglustat had lower severity score compared to those not treated with miglustat. There was no association between NP-C1 disease severity and other CP or CP activity parameters examined. 43, 44 , which may exhibit mild to moderate phenotypes relative to the residual protein activity. However, due to the small human sample size, the statistical power was low and precludes the inclusion of specific mutations as a part of the statistical model analysis. Furthermore, changes in metal metabolism in human NP-C1 patients may be obscured by heterogeneous genetic backgrounds and environmental factors. For example, the biochemical manifestations and the age of disease onset in the NP-C1 patients may be modified by additional genetic factors, such as the Apo-ε4 genotype 45 . It is noteworthy that ApoE binds transition metals, with highest affinity for copper 46 . The combination of cysteine and arginine at the isoform-defining positions 112 and 158 may result in differential metal metabolism in NP-C1
DISCUSSION
patients. Moreover, metal metabolism in humans is sensitive to variations in diet and intake of supplements/drugs that would not be a consideration in laboratory mice.
Peripheral copper dyshomeostasis has been associated with a loss of NPC1 function in an NP-C1 patient and the Npc1 -/-mouse model 11, 12, 16, 17 . We observed no significant difference in plasma copper level in the present NP-C1 patient cohort compared to HC (Table S6) . However, we did observe a late-disease stage increase in plasma copper in Npc1 -/-mice ( Figure 2B ) as previously reported 16 . This rise in plasma copper coincides with a significant increase in latedisease stage hepatic oxidative gene expression 13 . Thus, copper is likely a contributor to the rise in oxidative stress in Npc1 -/-mice. Disrupted copper homeostasis is widespread in all Npc1
-/-mouse tissue types examined, with the most dramatic change of a 170 ± 17% increase in the lungs. It is possible that the copper-induced oxidative stress in the lungs may contribute to the pulmonary abnormalities reported in animal model studies 47, 48 .
CP is a multi-copper oxidase that plays an important role in copper and iron metabolism, and it may serve as a surrogate peripheral marker of copper status. Consistent with our finding of normal plasma copper levels in NP-C1 patients, the plasma levels of all CP species, holo-CP oxidase activity and Cu:holo-CP ratio analyzed in this study remained unchanged between the HC and the NP-C1 patients not taking miglustat ( Figure 7 and Table S6 ). However, there was a small but significant decrease in plasma iron compared to HC ( Figure 6B and Table S6 ) that cannot be explained by the apparent normal holo-CP activity. It should be noted that despite an apparent increase in holo-CP in NP-C1 patients treated with miglustat, the Cu:holo-CP ratio and holo-CP specific activity were significantly decreased compared to NP-C1 patients not treated with miglustat and compared to HC. The negative impact of miglustat on CP specific activity suggests that glycosphingolipids may be important in regulating CP activity by an uncertain mechanism. Again, in contrast to the human data, and as previously reported 16 , there is a concomitant elevation of the plasma total CP level in symptomatic Npc1 -/-mice ( Figure 2D ). In this study we further demonstrated that this corresponds to increased copper-bound holo-CP and CP oxidase activity ( Figure 2F and 2G) . This difference between human and mouse plasma CP and its oxidase activity may be explained by a species-specific difference in CP metabolism and activity 36 . In humans, CP accounts for 90 -100% of the plasma ferroxidase activity. In contrast, only about 50% of mouse plasma ferroxidase is attributable to CP, while the source of the remaining 50% is unknown. Furthermore, our in vivo human and mouse CP data do not support the in vitro finding that NPC1 regulates ATP7B trafficking to the secretory pathway, where ATP7B incorporates copper into CP 18, 19 . Further studies are required to resolve this apparent inconsistency.
Interestingly, there is an apparent copper deficiency in the CSF of NP-C1 patients, but a slightly higher total CP level compared to their respective reference ranges. There is a lack of association between CSF total and holo-CP with copper ( Figure 5B ), and the CSF Cu:CP ratio is 7 -8-folds greater than that observed in the plasma. Our finding is consistent with an earlier study that reported only a small fraction of copper is associated with CP in the CSF in both
Alzheimer's disease (AD) and control subjects 49 . We have limited knowledge of normal CP metabolism in the CSF, but the difference between peripheral and CSF Cu:CP ratios suggests discrete CP metabolism in these compartments. Collectively, these findings are consistent with the hypothesis that, unlike the plasma, the majority of the CSF copper is not CP-bound but binds
to an yet-to-be-identified ligand 50 . However, in contrast to decreased CSF holo-CP in AD, our analysis of the NP-C1 CSF revealed a modest but significant positive association between CSF total and holo-CP concentrations and disease severity ( Figure 5A ). CP is an acute phase marker and this association may reflect the increase in neuroinflammation in NP-C1 51 . Thus CSF CP may be a useful biomarker to monitor the disease progression and therapeutic response, in addition to the other CSF neuroinflammatory markers identified in the Cologna et al studyZinc is an essential trace element important to the development and survival of all organisms. It is particularly critical to the normal brain function, such as neurotransmission and signaling 52, 53 . In Npc1 -/-mice, there was an early, pre-symptomatic increase in plasma zinc compared to WT animals at P21, which appeared to normalize by P49 ( Figure 2C and Table S1 ).
Interestingly, an MRI study has revealed that pre-symptomatic 3-week old Npc1 -/-mice exhibit a loss of white matter 54 . Combined with the age-dependent increase in plasma copper in symptomatic Npc1 -/-mice at P49, the observed changes in plasma copper and zinc could serve as pre-and symptomatic biomarkers in the Npc1 -/-mouse model. However, in NP-C1 patients, plasma zinc is significantly decreased compared to HC and they are more frequently below the reference range ( Figure 6C and Table S6 ). Also, this apparent zinc deficiency is not corrected by miglustat treatment. It is noteworthy that hepatosplenomegaly is associated with human serum/plasma zinc deficiency 55, 56 , and is a complication of NP-C. Despite the inconsistencies in changes in plasma zinc between NP-C1 patients and Npc1 -/-mice, both species demonstrate brain zinc overload (Figure 1 and 3 , Tables S1 and S4). Excess brain zinc can promote tau expression, phosphorylation and aggregation, possibly contributing to the formation of pathological neurofibrillary tangles (NFTs) in NP-C [57] [58] [59] [60] [61] [62] [63] . Furthermore, zinc also accumulates in brain tissues from ovine and murine models of CLN6 neuronal ceroid lipofuscinosis (Batten disease), a lysosomal storage disease 64, 65 . Thus, brain zinc accumulation is an emerging common pathological feature associated with neurodegeneration in lysosomal storage disorders.
CONCLUSIONS
The findings in this study support a novel role for NPC1 in the regulation of metal metabolism, although its impact on human and mouse metal metabolism may differ. We hypothesize that since the lysosome is believed to play a critical role in the uptake and sorting of transition metals 66 , the lesion of NPC1 may perturb metal homeostasis by disrupting lysosomaldependent sorting mechanisms. It is notable that miglustat does not correct the perturbed plasma manganese, iron and zinc levels and disrupts plasma CP chemistry in NP-C1 patients. Future therapeutic strategies for NP-C1 may need to consider the failure in metal metabolism to improve treatment efficacy.
Page 20 of 38 Metallomics
Figure legends The CSF Mn concentration was significantly associated with both total and holo-CP levels. CSF total, holo-and apo-CP concentrations were measured using purified human CP standards and western blotting (see Figure S2A ). Statistical analysis: multiple linear regression was performed, adjusting for age and gender (n = 21). Shaded areas denote 95% confidence interval. Plasma total, holo-and apo-CP concentrations were measured using purified human CP
